Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Beats Expectations By $1.67 EPS

Key Points

• Big beat: Jazz reported Q1 non‑GAAP EPS of $6.34, beating estimates by $1.67, with revenue of $1.07B (+19% YoY) and management reaffirming full‑year revenue guidance of $4.25–4.5B.
• Ziihera on fast track: The sBLA for zanidatamab (Ziihera) was accepted under Real‑Time Oncology Review with priority review and a PDUFA date of Aug. 25, 2026, and the company plans to launch immediately on approval amid multiple upcoming clinical readouts.
• Mixed commercial outlook: Core products showed momentum (XYWAV $408M, Epidiolex $250M, Zepzelca $101M), but management warned of second‑half headwinds from high‑sodium oxybate generics, new wake‑promoting entrants and expected declines in some franchise sales.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) released its earnings results on Tuesday. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter, topping analysts' consensus estimates of $4.67 by $1.67, FiscalAI reports. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals's revenue was up 19.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.68 EPS.

Here are the key takeaways from Jazz Pharmaceuticals' conference call:

• Record Q1 results — total revenue of $1.07B (+19% YoY), non-GAAP adjusted EPS of $6.34 and $408M cash from operations, and management reaffirmed full‑year revenue guidance of $4.25–4.5B.
• Ziihera (zanidatamab) sBLA accepted under Real‑Time Oncology Review with priority review and a PDUFA date of August 25, 2026; company highlights HERIZON‑GEA‑01 data (triplet median OS 26.4 months) and plans to launch immediately on approval.
• Broad commercial momentum — XYWAV $408M (18% growth, ~16,600 active patients), Epidiolex $250M (15% growth, 16% volume growth), Zepzelca $101M (60% growth) and Modeyso $41M with ~500 patients treated and a stated ~$500M peak potential.
• Multiple upcoming clinical catalysts that could drive value — mid‑year second interim OS readout for zanidatamab in GEA, ACTION (Modeyso) topline expected late‑2026/early‑2027, and EmpowHER (breast cancer) enrollment on track for top‑line in late‑2027/early‑2028.
• Management cautions on second‑half headwinds — anticipated growth of high‑sodium oxybate generics and possible new wake‑promoting entrants (and declining XYREM/authorized generic sales) could pressure the oxybate franchise, and Zepzelca second‑line use is expected to decline.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded up $4.20 during midday trading on Tuesday, reaching $212.26. The stock had a trading volume of 1,214,968 shares, compared to its average volume of 920,288. The firm has a fifty day simple moving average of $190.45 and a two-hundred day simple moving average of $171.65. Jazz Pharmaceuticals has a 12-month low of $97.50 and a 12-month high of $212.57. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The stock has a market cap of $13.32 billion, a P/E ratio of -35.55, a P/E/G ratio of 0.36 and a beta of 0.27.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JAZZ shares. Needham & Company LLC increased their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a "buy" rating in a research note on Monday, January 12th. Leerink Partners raised their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. TD Cowen restated a "buy" rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada raised their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $216.87.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares of the company's stock, valued at approximately $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 55,600 shares of the firm's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president directly owned 56,862 shares of the company's stock, valued at approximately $10,892,484.72. This trade represents a 49.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 74,015 shares of company stock valued at $14,180,486 in the last quarter. Corporate insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at $40,000. Caitong International Asset Management Co. Ltd lifted its holdings in Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 332 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 137 shares during the period. Sunbelt Securities Inc. acquired a new stake in Jazz Pharmaceuticals in the third quarter valued at $53,000. Finally, Kestra Advisory Services LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $63,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.